Literature DB >> 16108982

Blink rate in boys with fragile X syndrome: preliminary evidence for altered dopamine function.

J E Roberts1, F J Symons, A-M Johnson, D D Hatton, M L Boccia.   

Abstract

BACKGROUND: Dopamine, a neurotransmitter involved in motor and cognitive functioning, can be non-invasively measured via observation of spontaneous blink rates. Blink rates have been studied in a number of clinical conditions including schizophrenia, autism, Parkinsons, and attention deficit/hyperactivity disorder with results implicating either hyper or hypo dopaminergic states.
METHODS: This study examined spontaneous blink rate in boys with fragile X syndrome (FXS). Blink rates of boys (4-8 years old) with FXS (n = 6) were compared with those of age-matched typically developing boys (n = 6) during active and passive tasks. Blink rates (blinks per minute) for each task were compared between the two groups. Then, the relation between blink measures and core FXS-related features [problem behaviours, arousal, fmr 1 protein (FMRP)] were examined within the group of boys with FXS.
RESULTS: Blink rate in boys with FXS was significantly higher than typically developing boys during passive tasks. Within the FXS group, there were significant correlations between blink rate and problem behaviours and physiological arousal (i.e. heart activity) but not with FMRP.
CONCLUSIONS: Observed differences in spontaneous blink rate between boys with and without FXS and the relation between blink rate and physiological and behavioural measures in boys with FXS suggests that further work examining dopamine dysfunction as a factor in the pathophysiology of FXS may be warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108982     DOI: 10.1111/j.1365-2788.2005.00713.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  9 in total

1.  Intraindividual and Interindividual Differences in Spontaneous Eye Blinking: Relationships to Working Memory Performance and Frontal EEG Asymmetry.

Authors:  Leigh F Bacher; Shirley Retz; Courtney Lindon; Martha Ann Bell
Journal:  Infancy       Date:  2016-09-14

2.  Dampened dopamine-mediated neuromodulation in prefrontal cortex of fragile X mice.

Authors:  Kush Paul; Deepa V Venkitaramani; Charles L Cox
Journal:  J Physiol       Date:  2012-11-12       Impact factor: 5.182

Review 3.  Public Health Literature Review of Fragile X Syndrome.

Authors:  Melissa Raspa; Anne C Wheeler; Catharine Riley
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

4.  Autonomic regulation in fragile X syndrome.

Authors:  Keri J Heilman; Emily R Harden; Danielle M Zageris; Elizabeth Berry-Kravis; Stephen W Porges
Journal:  Dev Psychobiol       Date:  2011-05-05       Impact factor: 3.038

5.  Anhedonia and Hyperhedonia in Autism and Related Neurodevelopmental Disorders.

Authors:  Gabriel S Dichter; Jose Rodriguez-Romaguera
Journal:  Curr Top Behav Neurosci       Date:  2022

6.  Delineation of early attentional control difficulties in fragile X syndrome: focus on neurocomputational changes.

Authors:  Gaia Scerif; Kim Cornish; John Wilding; Jon Driver; Annette Karmiloff-Smith
Journal:  Neuropsychologia       Date:  2007-01-24       Impact factor: 3.139

7.  Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings.

Authors:  Gabriel S Dichter; Cara A Damiano; John A Allen
Journal:  J Neurodev Disord       Date:  2012-07-06       Impact factor: 4.025

8.  Repetitive and self-injurious behaviors: associations with caudate volume in autism and fragile X syndrome.

Authors:  Jason J Wolff; Heather C Hazlett; Amy A Lightbody; Allan L Reiss; Joseph Piven
Journal:  J Neurodev Disord       Date:  2013-05-02       Impact factor: 4.025

Review 9.  Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.

Authors:  Hansen Wang; Sandipan Pati; Lucas Pozzo-Miller; Laurie C Doering
Journal:  Front Cell Neurosci       Date:  2015-02-26       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.